Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 366 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Copegus Clear all
Completed Phase 4 Interventional Results available

Study of Oral Treatments for Hepatitis C

NCT02786537
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 17, 2026, 7:16 PM EDT
Terminated Phase 1 Interventional

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

NCT01377909
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
statin
Drug
Lead sponsor
Bader, Ted, M.D.
Individual
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

NCT01052701
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Ribavirin, Ribavirin plus Abacavir (ABC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

NCT00665353
View directory record Official record
Conditions
HIV-1 and Hepatitis C Co-Infection
Interventions
pioglitazone, peginterferon, ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

NCT02032875
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT01314261
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions
ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

NCT02939989
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
8
States / cities
Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00743795
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
48
States / cities
Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 17, 2026, 7:16 PM EDT
Withdrawn Phase 4 Interventional

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

NCT01415141
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon alfa-2a, Ribavirin, telaprevir
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma

NCT01268579
View directory record Official record
Conditions
HEAD & NECK Cancer
Interventions
ribavirin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

NCT01808248
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

NCT01701401
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

NCT01938430
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Results available

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Peginterferon alfa-2a with Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

NCT02536313
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

NCT01479868
View directory record Official record
Conditions
Hepatitis C Virus Genotype-1
Interventions
TMC435, Pegylated interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 17, 2026, 7:16 PM EDT
Withdrawn Phase 2 Interventional

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

NCT01142700
View directory record Official record
Conditions
Chronic Hepatitis C Virus Genotype 1
Interventions
BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Oct 17, 2026, 7:16 PM EDT
Terminated Phase 4 Interventional Results available

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

NCT01467492
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

NCT00545233
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

NCT02468648
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Sofosbuvir, GS-5816
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

NCT01227967
View directory record Official record
Conditions
Influenza
Interventions
Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 17, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Results available

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

NCT00394277
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 17, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 7:16 PM EDT